This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Jun;6(6):300.

doi: 10.1038/nrendo.2010.56.

Obesity: Taranabant no longer developed as an antiobesity agent

PMID: 20518102
DOI: 10.1038/nrendo.2010.56

Comment

Obesity: Taranabant no longer developed as an antiobesity agent

Linda Koch. Nat Rev Endocrinol. 2010 Jun.

. 2010 Jun;6(6):300.

doi: 10.1038/nrendo.2010.56.

Author

PMID: 20518102
DOI: 10.1038/nrendo.2010.56

No abstract available

PubMed Disclaimer

Comment on

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM. Aronne LJ, et al. Int J Obes (Lond). 2010 May;34(5):919-35. doi: 10.1038/ijo.2010.21. Epub 2010 Feb 16. Int J Obes (Lond). 2010. PMID: 20157323 Clinical Trial.

References

1. Int J Obes (Lond). 2010 May;34(5):919-35 - PubMed
1. Int J Obes (Lond). 2010 Aug;34(8):1243-54 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database